September 2023 in “Journal of the American Academy of Dermatology” Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.
September 2023 in “Journal of the American Academy of Dermatology”
December 2006 in “The Brown University Psychopharmacology Update” Second-generation antipsychotics offer no significant benefit over first-generation ones for schizophrenia.
2 citations
,
March 2020 in “Cns & Neurological Disorders-drug Targets” Lurasidone is effective for bipolar depression and schizophrenia, but more safety data is needed.
16 citations
,
February 2009 in “Clinical neurology and neurosurgery” Switching to extended-release divalproex sodium improved patient-reported tremor but did not change seizure frequency or most side effects.
4 citations
,
November 2001 in “Journal of Neuropsychiatry” Divalproex sodium can sometimes worsen behavior in some patients.
35 citations
,
August 2004 in “Epilepsy & behavior” Extended-release divalproex is better tolerated and more effective for seizures and psychiatric symptoms than delayed-release divalproex, but doesn't reduce hair loss.
34 citations
,
July 2011 in “International journal of pharmaceutics” Ion-paired risedronate significantly increases skin penetration without irritation compared to risedronate alone.
November 2001 in “The Journal of neuropsychiatry and clinical neurosciences/The journal of neuropsychiatry and clinical neurosciences” Divalproex sodium can unexpectedly cause agitation and hyperactivity in some patients.
53 citations
,
October 2011 in “Psychoneuroendocrinology” Finasteride may help improve certain brain function issues linked to dopamine.
1 citations
,
April 1987 in “American Journal of Nursing” Some drugs can cause serious side effects, like hypoglycemia from mix-ups, skin reactions, or depression, and while penicillamine may help rheumatoid arthritis more than auranofin, it has more severe side effects.
20 citations
,
September 1983 in “Archives of dermatology” The new synthetic retinoid RO 13-6298 effectively treated severe psoriasis at low doses with manageable side effects.
November 2006 in “Reactions Weekly” A woman's hair grew back after she stopped taking the Parkinson's disease medication pramipexole.
1 citations
,
October 2011 in “Hospital Pharmacy” 27 citations
,
April 2008 in “Neuroscience Letters” Olanzapine reduces stress-related anxiety in rats when given acutely.
September 2025 in “Healthcare” SSRIs may help manage sexual behavior in dementia patients, but they can cause long-lasting sexual dysfunction.
July 2023 in “Zenodo (CERN European Organization for Nuclear Research)” Trazodone and chlorpromazine may help treat sexual dysfunction caused by finasteride and SSRIs.
April 2026 in “Therapeutic Advances in Drug Safety” Finasteride is high-risk for cognitive disorders, while Carbidopa/Levodopa, Topiramate, and Clonazepam are moderate-risk.
12 citations
,
June 2019 in “Psychoneuroendocrinology” Allopregnanolone is needed for certain brain processing issues caused by D1 dopamine receptor activation.
2 citations
,
March 2023 in “Experimental neurology” Pregnenolone might help manage movement issues caused by Parkinson's disease treatment without reducing the medicine's effectiveness.
15 citations
,
June 2019 in “Journal of Neuroendocrinology” Isoallopregnanolone may be a safe and effective treatment for reducing tics in a mouse model of Tourette syndrome.
5 citations
,
July 2017 in “Skin appendage disorders” A man got a rare rash from the drug topiramate, which went away after he stopped taking it.
21 citations
,
March 2002 in “Neurology” Dopamine agonists like pramipexole and ropinirole can cause reversible hair loss.
January 2013 in “Chinese Journal of Hospital Pharmacy” A reliable method was developed to measure perospirone levels in human plasma for clinical use.
64 citations
,
March 2008 in “Neuropsychopharmacology” 49 citations
,
September 2015 in “Psychoneuroendocrinology” 5α-reductase affects dopamine receptors linked to sensorimotor gating, which may help understand disorders like schizophrenia.
April 2025 in “European Psychiatry” Mood stabilizers for bipolar disorder can cause skin issues, but severe reactions are rare.
20 citations
,
August 2008 in “Journal of Medical Case Reports” Ondansetron can cause serious allergic reactions, so use it carefully.
November 2010 in “International Journal of Developmental Neuroscience” Blocking 5α-reductase can reduce sleep deprivation-related behavioral issues in rats.